Business
Lipocine Announces Third Quarter 2020 Financial and Operational Results
SALT LAKE CITY, Nov. 10, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine
About this update from Lipocine Inc.
[{"type":"text","content":"SALT LAKE CITY, Nov. 10, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update.\n\n \n \n \n \n \n \n\n \nThird Quarter and Recent Corporate Highlights\nCompleted patient enrollment in the LPCN 1144 Phase 2 LiFT (\"Liver Fat intervention with oral Testosterone\") clinical study, a paired-biopsy study in confirmed pre-cirrhotic NASH subjects Top-line results for change in liver fat data measured by MRI-PDFF (primary endpoint) expected in January 2021 and 36-week biopsy and MRI-PDFF data expected mid-2021Announced the peer-reviewed publication of LPCN 1144 Liver Fat Study results, \"LPCN 1144 Resolves Non-Alcoholic Fatty Liver Disease in Hypogonadal Males\" in Hepatology Communications Presented two abstracts at the 21st Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (\"SMSNA\") A study on the potential use of oral testosterone in COVID-19 highlighted key clinical evidence suggesting that low testosterone levels may play an important role on clinical outcomes Results from a 24-day, open-label, single-arm, multicenter study confirming the validity of a fixed dose approach to orally administering TLANDO™ in hypogonadal men without the need for dose titration. Ongoing Activities and Upcoming Milestones\nPresenting results from a preclinical study investigating LPCN 1144 treatment on hepatic fibrosis and non-alcoholic steatohepatitis (\"NASH\") features will be presented at The Liver Meeting Digital Experience™, hosted by the American Association for the Study of Liver Diseases (\"AASLD\") on November 13, 2020 Announcing decision from U.S. Food and Drug Administration (\"FDA\") on the New Drug Application (\"NDA\") for TLANDO™ Third Quarter Ended September 30, 2020 Financial ResultsLipocine reported a net loss of $4.3 million, or ($0.07) per basic and diluted share, for the quarter ended September 30, 2020, compared with a net loss of $3.1 million, or ($0.12) per basic and diluted share, in the quarter ended September 30, 2019.\nResearch and development expenses were $2.5 million for the quarter ended September 30, 2020, compared with $1.7 million for the quarter ended September 30, 2019. The increase in res...